Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Celldex Therapeutics Inc.

Celldex Therapeutics ($CLDX) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is launching a Phase 1 study...

Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX

Mizuho Securities analyst reiterated a Buy rating on Celldex today and set a price target of $48.00. Currently, the analyst consensus on Celldex is...

Celldex (CLDX) Gets a Buy from Mizuho Securities

In a report released today, Etzer Darout from Barclays maintained a Sell rating on Celldex, with a price target of $24.00. According to TipRanks, D...

Barclays Remains a Sell on Celldex (CLDX)

Celldex Therapeutics ($CLDX) announced an update on their ongoing clinical study. Study Overview Celldex Therapeutics (CLDX) is running a late-stag...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLDX	$25.20	+2.19%	433.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CLDX	$25.20	+2.2%	433.66K
3
4
5
6

CLDX

CLDX

No Data Available

Get Celldex Therapeutics Inc. Data in Excel

Get Celldex Therapeutics Inc. Data in Excel